雌激素、肿瘤标志物联合DCE-MRI在宫颈癌诊断及临床分期中的应用
|
左冰玉, 石丽莉, 宋佳, 赵阳, 李倩
|
Application of Estrogen and Tumor Markers Combined with DCE-MRI in Diagnosis and Clinical Staging of Cervical Cancer
|
ZUO Bingyu, SHI Lili, SONG Jia, ZHAO Yang, LI Qian
|
|
表3 研究组不同临床分期宫颈癌患者血清雌激素及肿瘤标志物水平比较
|
Table 3 Comparison of levels of serum estrogen and tumor markers in cervical cancer patients with different clinical stages
|
|
分组 | 样本数(n) | E2/(pmol/L) | FSH/(mIU/mL) | LH/(mIU/mL) | CA125/(U/mL) | CA19-9/(U/mL) | I期宫颈癌 | 25 | 268.88±2.15 | 191.72±1.87 | 201.09±0.25 | 195.92±0.08 | 205.02±2.18 | Ⅱ期宫颈癌 | 24 | 278.39±2.83* | 197.44±2.65* | 209.99±2.32* | 205.98±2.69* | 211.28±2.47* | Ⅲ期宫颈癌 | 19 | 289.87±3.35*# | 207.49±3.61*# | 219.08±3.21*# | 212.99±3.34*# | 218.34±3.62*# | Ⅳ期宫颈癌 | 19 | 287.16±5.94*# | 208.82±2.19*# | 219.56±0.16*# | 213.52±3.23*# | 217.91±4.19*# | F | | 143.800 | 214.700 | 467.900 | 507.200 | 90.540 | P | | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
|
|
|